AutoCart[™]

Single-Stage Articular Cartilage Repair



AutoCart™

Single-Stage Articular Cartilage Repair

The AutoCart surgical technique is designed to treat symptomatic articular cartilage defects through a single-stage, matrix-augmented autologous chondrocyte transplantation. This procedure uses articular cartilage harvested with the GraftNet[™] device, which is then combined with BioCartilage* extracellular matrix (ECM). The resulting mixture of autologous osteochondral tissue and BioCartilage ECM is further enhanced with Arthrex ACP* platelet-rich plasma (PRP). Finally, the composite graft is sealed into the prepared defect using Thrombinator* autologous thrombin serum. Together, these components provide a streamlined, biologic solution for addressing focal osteochondral defects in a single surgical session.

Scientific Support for the AutoCart Procedure

ANALYSIS OF THE ONE-STAGE AUTOLOGOUS PARTICULATE CARTILAGE IMPLANTATION

One-step autologous minced cartilage procedure for the treatment of knee joint chondral and osteochondral lesions: a series of 27 patients with 2-year follow-up.

Massen FK, Inauen CR, Harder LP, Runer A, Preiss S, Salzmann GM

- > Prospective clinical trial of single-stage reimplantation of autologous cartilage particles for chondral/osteochondral lesions of the knee joint in 27 patients with a follow-up period of 2 years
- > The surgical procedure proved to be safe and showed no failure rate; patient-reported NAS pain scores showed significant improvement from 7.2 ± 1.9 to 2.3 ± 2.0 at 1 year and 1.8 ± 1.6 at 2 years; patient-reported functional scores showed similar results
- > After treatment, 92.6 % of patients reported that they would choose the surgical procedure again

Takeaway: Based on the short-term clinical results of this study, the authors concluded single-stage autologous chondrocyte transplantation has been shown to be a safe and well-accepted procedure for the treatment of focal cartilage damage. The patient-relevant assessments regarding postoperative pain and function show promising results.

Orthop J Sports Med. 2019;7(6):2325967119853773. doi:10.1177/2325967119853773

CHONDROCYTE COLLECTION AND VIABILITY WITH THE GRAFTNET DEVICE

Comparison of human articular cartilage tissue and chondrocytes isolated from peripheral versus central regions of traumatic lesions.

Acevedo L, Iselin L, Berkelaar MHM, Salzmann GM, Wolf F, Feliciano S, Vogel N, Pagenstert G, Martin I, Pelttari K, Barbero A, Arnold MP

- > Analyzed cartilage from the central and peripheral regions of traumatic joint injuries for tissue quality, viability, and proliferation capability of the minced cartilage
- > Peripheral cartilage had similar cellularity and proliferation rate to the central cartilage samples
- > Peripheral cartilage had increased cartilage quality compared to central cartilage, while central cartilage had an increase in cartilage viability; however, the peripheral cell viability was still at 96.8% viability, which is well above the acceptable percentage for implantation

Takeaway: Peripheral cartilage surrounding a traumatic lesion may provide cartilage with high quality, acceptable chondrocyte viability, and acceptable cellularity. It also maintains proliferative potential.

Cartilage. 2021;13(2_suppl):68S-81S. doi:10.1177/1947603520958154

AUTOLOGOUS GRAFT STABILITY AND FIXATION WITH THE THROMBINATOR™ DEVICE

The clot thickens: autologous and allogeneic fibrin sealants are mechanically equivalent in an ex vivo model of cartilage repair.

Irwin RM, Bonassar LJ, Cohen I, Matuska AM, Commins J, Cole B, Fortier LA

- > Study comparing allogeneic fibrin glue and autologously produced fibrin/thrombin scaffold from platelet-poor plasma (PPP)/PRP
- > The autologous scaffold fixation with PPP/PRP showed the same mechanical quality as an allogeneic product in all aspects considered

Takeaway: The use of an autologous fixation solution of cartilage particles in the regenerate allows equal mechanical stability and autograft integration, with lower thombin/fibrin concentration than allogeneic fixations. This may lead to better integration of the autograft and defect healing.

PLoS One. 2019;14(11):e0224756. doi:10.1371/journal.pone.0224756

CLINICAL RESULTS FOR THE AUTOCART™ PROCEDURE

Outcomes after a single-stage procedure for cell-based cartilage repair: a prospective clinical safety trial with 2-year follow-up.

Cole BJ, Farr J, Winalski CS, Hosea T, Richmond J, Mandelbaum B, De Deyne PG

- > Analysis of the safety and clinical outcomes of a single-stage cartilage autograft implantation system
- > After 24 months, the single-stage autograft implantation technique provided significantly improved IKDC and KOOS patient scores when compared to microfracture
- > Single-stage autograft implantation showed a decreased incidence of intralesional osteophyte formation at 6- and 12-month follow-ups

Takeaway: Compared to microfracture, single-stage autograft cartilage implantation provides superior patient outcomes and decreased negative outcomes associated with osteophyte formation.

Am J Sports Med. 2011;39(6):1170-1179. doi:10.1177/0363546511399382


Arthroscopic autologous minced cartilage implantation of cartilage defects in the knee: a 2-year follow-up of 62 patients.

Schneider S, Ossendorff R, Walter SG, Berger M, Endler C, Kaiser R, Ilg A, Salzmann GM, Holz J

- > Case series followed 62 patients treated with the AutoCart technique up to 2-years postsurgery (34 male, 28 female, mean age 38.79 \pm 10.78 years)
- > Patients had a mean defect size of 2.53 cm², with 40.3% undergoing concomitant procedures
- > Total KOOS scores significantly improved from 62.4 ± 13.1 at baseline to 74.4 ± 15.9 at 2 years (P < .001)
- > Secondary outcome measures—VAS, WOMAC, and SANE—also improved significantly at 2-year follow-up as compared to baseline

Takeaway: Clinical and radiological outcomes were comparable to other frequently used cartilage repair techniques, supporting the AutoCart procedure as a safe and effective cartilage repair treatment option.

 $\textit{Orthop J Sports Med.}\ 2024; 12 (12): 23259671241297970.\ doi: 10.1177/23259671241297970$



The Healing Triad

Successful tissue formation requires 3 main components: a scaffold, growth factors, and regenerative cells. These components form the "healing triad." A scaffold is needed to provide a structure for tissue growth. It assures mechanical integrity and provides a substrate for cell growth. Growth factors are bioactive signaling molecules. They induce differentiation, proliferation, and metabolic activity and determine the phenotype of the cells. Regenerative cells, such as vital chondrocytes, also stimulate tissue regeneration.

In the case of cartilage restoration, the healing triad describes the combined use of vital chondrocytes and osteocytes (regenerative cells), PRP (growth factors), extracellular chondral fragments, and an autologous thrombin solution (scaffolds).

Augmentation with BioCartilage® ECM may act as a scaffold to improve graft handling during delivery and aid tissue fill of the prepared osteochondral defect.¹⁻⁵









Shaver Blades

For harvesting chondrocytes and autologous cartilage tissue



GraftNet™ Autologous tissue collector







AutoCartTM

SINGLE-STAGE CARTILAGE **REPAIR**









BioCartilage® ECM

For the preparation of growth factors to be mixed with the osteochondral graft









Arthrex ACP® Platelet-Rich Plasma

For the preparation of growth factors









Thrombinator™ System

For the preparation of autologous thrombin serum

Shaver Blades











Introduction

Use a 3 mm Sabre shaver blade or 4 mm BoneCutter shaver blade to harvest autologous chondral and osteochondral fragments. Tissue is harvested either from the edge of the lesion or from a non–load-bearing area. Using these shaver blades produces fragments approximately 1 mm across while maintaining good chondrocyte vitality.³

Arthroscopic Shaver Blades With Cartilage Fragments⁶




BoneCutter shaver blade, 4 mm (BC4)




Sabre shaver blade, 4 mm (S4)




Torpedo™ shaver blade, 4 mm (T4)




Sabre shaver blade, 3 mm (S3)



Excalibur shaver blade, 4 mm (E4)







Diagrams: Lifetime~(24~hours,~4~days,~and~7~days)~of~chondrocytes~in~the~cartilage~particles~harvested~using~the~shaver~blade.

Particle size distribution (area) for various shaver blades⁶

GraftNet™







Autologous Tissue Collector



Introduction

The suction-activated GraftNet device allows for efficient collection of autologous tissue to incorporate the patient's own cells into the graft. After mounting the GraftNet tissue collector between the shaver handpiece and the suction system, the autologous osteochondral fragments are collected in an easily accessible, sterile filter chamber. Open the tissue collector and remove the filter chamber and osteochondral fragments.

Features and Benefits

- > Universal adapters make for easy assembly
- > Harvest autologous bone or cartilage fragments
- > Quick access to the harvested tissue
- > Control over particle size when using a shaver blade system

BioCartilage®







ECM

Composition

- > BioCartilage ECM contains the ECM that is native to articular cartilage, including key components such as type II collagen (Figure 1), proteoglycans (Figure 2), and additional cartilaginous growth factors
- > After processing, the dehydrated allograft cartilage has a particle size of 100 $\mu m\text{-}300~\mu m$:
 - > The small particle size improves its injectable nature after it is mixed with an autologous blood solution, allowing easier delivery to the defect site
 - The small particle size also increases the surface area, providing attachment sites for the patient's bone marrow cells^{7,8} (Figures 3 and 4 depict the ability of progenitor cells to attach to BioCartilage ECM)

Processing

> BioCartilage ECM is terminally sterilized using electron beam (e-beam) irradiation to a sterility assurance level (SAL) of 10-6. The graft is packaged to allow for ambient temperature storage with a shelf life of 5 years.




Figure 1. Immunohistochemistry staining for type II collagen



Figure 2. Proteoglycan content as evidenced by the presence of interterritorial granular matrix via toluidine blue staining

Attachment of Progenitor Cells to BioCartilage ECM



Figure 3.




Figure 4. The tissue was stained after dehydration, before micronization

Arthrex ACP® Double Syringe









Introduction

The Arthrex ACP double syringe is used for the preparation of PRP and associated concentrated growth factors.

How It Works

Platelets release proliferative and morphogenetic proteins. These proteins appear to work in synergy to produce the following positive effects⁹⁻¹¹:

- Induce proliferation and differentiation of various cell types (such as progenitor cells, osteoblasts, and epidermal cells)
- Enhance/modulate production of collagen, proteoglycan, and tissue inhibitors of metalloproteinases (TIMP)
- > Stimulate angiogenesis and chemotaxis

Features and Benefits of the Arthrex ACP Double Syringe

- > Unique 2-in-1 system for preparation of ACP
- > ACP preparation and use takes just minutes
- > Closed, sterile system
- > Simple, practical, and easy to use

Thrombinator™ System







For Preparation of Autologous Thrombin Serum



Introduction

The Thrombinator system, for use with the Arthrex PRP systems, is designed to obtain an autologous thrombin solution directly at the point of care. Autologous thrombin solution improves handling and fixation by causing platelets to form a gel that serves as a binding agent for bone/cartilage graft material when treating an osteochondral defect.


The Thrombinator process uses the clotting cascade mechanism to produce an autologous thrombin solution and avoids the use of aggressive chemical reagents such as ethanol. The design of the Thrombinator device eliminates the need for prolonged incubation times and heating. An autologous thrombin solution can be produced in as little as 22 minutes.

Features and Benefits

- > Preparation from whole blood (WB), PRP, or PPP
- > Produces clotting in as little as 15 seconds
- > Does not require centrifugation or heating

User Instructions

Preparation of ACP



1

Draw 15 mL venous blood using Arthrex ACP* double syringes, then seal the double syringes using the red caps.

Note: Depending on the desired volume of autologous fluid necessary for the Thrombinator™ device and when mixing with the autograft tissue, adjust the starting volume of whole blood and processing times as needed.



2

Centrifuge at 1500 rpm for 5 minutes.



3

To transfer the ACP from the larger outer syringe into the small inner syringe, slowly push down on the syringe's red wings.



4

Unscrew the small syringe from the large syringe.

Preparation of Autologous Thrombin Solution



1

Add 0.1 mL CaCl and 4 mL autologous blood fraction (PRP, PPP, or WB) through the "Inject" port. The CaCl should be added first, followed by the autologous blood fraction.



2

Mix for 5 seconds.



3

Place the Thrombinator™ device flat with "Withdraw" side up and wait a minimum of 15-20 minutes or until signs of gelling occur. Avoid picking up the device during this time.



4

Shake for 5 seconds to break the clot.



5

Add 0.2 mL CaCl and 8 mL autologous blood fraction through the "Inject" port. The CaCl should be added first, followed by the autologous blood fraction.



6

Mix for 5 seconds.



7

Place the Thrombinator $^{\!\scriptscriptstyle{\text{\tiny M}}}$ device flat with "Withdraw" side up and wait 1-2 minutes. Avoid picking up the device during this time.



8

Shake for 5 seconds to break the clot.



9

Place the Thrombinator device flat with "Withdraw" side up and wait 1-2 minutes. Avoid picking up the device during this time.



10

Shake for 5 seconds to break the clot.



11


Connect the filter to the "withdraw" port. Invert the device at a 45° angle toward the "withdraw" port and withdraw serum through the filter.



12

Use serum within 15 minutes of withdrawal from device.

AutoCart™ Graft Preparation



1

Mount the $\mathsf{GraftNet}^\mathsf{m}$ tissue collector between the shaver handpiece and tubing system.



2

Debride and prepare the cartilage defect as appropriate. Take care to create vertical margins.



3

Harvest chondral fragments from around the lesion border. Alternatively, resect healthy osteochondral fragments from another typical osteochondral harvest location (ie, another place on the same knee).




4

The harvested osteochondral fragments are collected in the tissue collector.



5

Separate the tissue collector from the handpiece and tubing system. Open the collector and carefully take out the plunger.





6


Using the mixing and delivery system, first remove the syringe cap and snap on the funnel to the end of the mixing syringe. Make sure the plunger is at the end of the syringe. Empty the GraftNet autologous osteochondral tissue and BioCartilage® ECM from their container into the funnel. The desired ratio is 1:1.



Remove the funnel and add ACP into the mixing syringe with a 1:0.8 ratio (BioCartilage ECM and GraftNetdevice-collected osteochondral tissue to autologous fluid). Twist on the syringe cap and Luer cap.



Unsnap the pushrod from the mixing element by pressing on the tip of the mixing element with counter-pressure on the tip of the pushrod.



9

Push and pull the mixing element back and forth while rotating it in a repeated left-to-right motion. Continue until thoroughly mixed.



10

Pull back on the mixing element to bring it back to its starting position.



11


Snap the pushrod back onto the mixing element.




12

Ensure the defect is dry and prepared for graft delivery. Attach a delivery cannula and dispense the $AutoCart^{m}$ graft out of the mixing syringe. Use the obturator to deliver the entire mixture.

Autologous Thrombin Mixture and Delivery



After preparing for graft fixation, carefully cover the fragment paste with the prepared thrombin serum. Start from the top. The Thrombinator $\mbox{\ensuremath{}^{\text{\tiny{M}}}}$ method relies on the blood clotting cascade mechanism. The combination of the fibrinogen contained in the paste and the thrombin applied creates a stable clot that holds the osteochondral mixture in the lesion.



2

After mixing, apply the mixture quickly to the lesion from the top, drop by drop, then wait for approximately 2 minutes.




3

A 1:1 mixing and delivery applicator can be used to simultaneously deliver a fibrinogen source platelet-poor plasma, PRP, or whole blood with the thrombin serum.

Quick Guide to Procedure

This diagram shows the approximate chronological sequence of the individual procedural steps and includes information about when blood must be processed in parallel (depending on the system selected). The times are for guidance only and may vary.

Workflow



Ordering Information

GraftNet™ Device	
GraftNet autologous tissue collector	ABS-1050
BioCartilage® ECM	
BioCartilage ECM, 1 cc	ABS-1010-BC
Mixing and Delivery Kit, large joint (includes mixing syringe and arthroscopic delivery needle, obturator, funnel, fat pad retractor, and cannulated swabs)	ABS-1000-L
Mixing and Delivery Kit, small joint (includes mixing syringe and cap, arthroscopic delivery needle, obturator, funnel, fat pad retractor, and cannulated swabs)	ABS-1000-S
Mixing and Delivery Kit, hip joint (includes mixing syringe and cap, arthroscopic delivery needle, obturator, funnel, fat pad retractor, and suction adaptor)	ABS-1000-H
Arthrex ACP® Double-Syringe System	
Arthrex ACP double syringe	ABS-10014
Arthrex ACP kit, series I	ABS-10011
Arthrex ACP kit, series II	ABS-10012
ACP Max™ PRP System	
ACP Max PRP system w/ ACD-A	ABS-10015
ACP Max PRP system	ABS-10013

Angel® cPRP System	
Angel PRP kit	ABS-10061T
Thrombinator™ System	
Thrombinator autologous thrombin serum	ABS-10080
Viscous Delivery Systems	
Applicator assembly 10 cc, 1:1 ratio	SA-3310
Dual cannula, malleable, 20 ga × 5 cm (2 in)	SA-3615
Dual cannula, malleable, 20 ga × 10 cm (4 in)	SA-3618
Dual cannula, malleable, 20 ga × 26 cm (10.25 in)	SA-3620
Shaver Blades and Bone Preparation	
Sabre shaver blade, 3 mm × 7 cm	AR-7300SR
Sabre shaver blade, 4 mm × 13 cm	AR-8400SR
BoneCutter, 3.8 mm × 13 cm	AR-8380BC
BoneCutter, 4 mm × 13 cm	AR-8400BC
PowerPick™ instrument, 30°, 1.5 mm × 13 cm	AR-8150PP-30
PowerPick instrument, 45°, 1.5 mm × 13 cm	AR-8150PP-45
PowerPick XL instrument, 45°, 6 mm drill depth	AR-8150PX-45

Products advertised in this brochure/surgical technique guide may not be available in all countries. For information on availability, please contact Arthrex Customer Service or your local Arthrex representative.

References

- Albrecht F, Roessner A, Zimmermann E. Closure of osteochondral lesions using chondral fragments and fibrin adhesive. Arch Orthop Trauma Surg (1978). 1983;101(3):213-217. doi:10.1007/BF00436773
- 2. Lu Y, Dhanaraj S, Wang Z, Bradley DM, Bowman SM, Cole BJ, Binette F. Minced cartilage without cell culture serves as an effective intraoperative cell source for cartilage repair. J Orthop Res. 2006;24(6):1261-1270. doi:10.1002/jor.20135
- 3. Stone KR, Walgenbach AW, Freyer A, Turek TJ, Speer DP. Articular cartilage paste grafting to full-thickness articular cartilage knee joint lesions: a 2- to 12-year follow-up. Arthroscopy. 2006;22(3):291-299. doi:10.1016/j.arthro.2005.12.051
- 4. Christensen BB, Foldager CB, Jensen J, Lind M. Autologous dual-tissue transplantation for osteochondral repair: early clinical and radiological results. Cartilage. 2015;6(3):166-173. doi:10.1177/1947603515580983
- 5. Massen FK, Inauen CR, Harder LP, Runer A, Preiss S, Salzmann GM. One-step autologous minced cartilage procedure for the treatment of knee joint chondral and osteochondral lesions: a series of 27 patients with 2-year follow-up. Orthop J Sports Med. 2019;7(6):2325967119853773. doi:10.1177/2325967119853773
- 6. Feeney E, Schaumann S, Benedict R, Matsuka A. Autologous cartilage particulate for treatment of cartilage defects: impact of different arthroscopic shavers on viability and in vitro migration. Poster presented at: Orthopedic Research Society 2020 Annual Conference; February 10-11, 2020; Phoenix, AZ.
- 7. Cheng N, Estes B, Awad H, et al. Chondrogenic differentiation of adipose-derived adult stem cells by a porous scaffold derived from native articular cartilage extracellular matrix. *Tissue Engineering*. 2009;15(2):231-41. doi:10.1089/ten.tea.2008.0253
- 8. Chadha N, Dang A, Sampson E, et al. Porous cartilage-derived matrix scaffolds for repair of articular cartilage defects. Poster presented at: Orthopaedic Research Society Annual Meeting; February 4-7, 2012; San Francisco, CA.
- 9. Borzini P, Mazzucco L. Tissue regeneration and in loco administration of platelet derivatives: clinical outcome, heterogeneous products, and heterogeneity of the effector mechanisms. *Transfusion*. 2005;45(11):1759-1767. doi:10.1111/j.1537-2995.2005.00600
- 10. Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJ, Angel P, Heath JK. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 1987;6(7):1899-1904. doi:10.1002/j.1460-2075.1987.tb02449.x
- 11. Lynch SE, Nixon JC, Colvin RB, Antoniades HN. Role of platelet-derived growth factor in wound healing: synergistic effects with other growth factors. *Proc Natl Acad Sci USA*. 1987;84(21):7696-7700. doi:10.1073/pnas.84.21.7696

This description of technique is provided as an educational tool and clinical aid to assist properly licensed medical professionals in the usage of specific Arthrex products. As part of this professional usage, the medical professional must use their professional judgment in making any final determinations in product usage and technique. In doing so, the medical professional should rely on their own training and experience and should conduct a thorough review of pertinent medical literature and the product's directions for use. Postoperative management is patient-specific and dependent on the treating professional's assessment. Individual results will vary and not all patients will experience the same postoperative activity level or outcomes.



Arthrex manufacturer, authorized representative, and importer information (Arthrex eIFUs)



US patent information